Research pipeline · Not approved
SurvodutideDual GLP-1 and glucagon receptor agonist
Survodutide is an investigational dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim, and the first in that class to publish Phase 3 results. It produced a mean weight reduction of 14.9% over 49 weeks. It is also being studied in metabolic dysfunction-associated steatotic liver disease. It holds no marketing authorisation and cannot lawfully be prescribed or supplied.
Not available
This compound is investigational. It holds no marketing authorisation from the MHRA, EMA or FDA, so it cannot lawfully be prescribed, sold or supplied for human use in the UK or elsewhere. Products offered online as "research use only" versions of it are unlicensed medicines, of unverified identity and purity, and are outside any clinical oversight.
At a glance
- Developer
- Boehringer Ingelheim
- Targets
- GLP-1 · Glucagon
- Administration
- Once-weekly subcutaneous injection (in trials)
- Stage
- Phase 3 trials
- Reported
- 14.9% · 49 weeks
How Survodutide differs
It pairs GLP-1 agonism with glucagon receptor agonism, but without the GIP component that tirzepatide and retatrutide carry.
The glucagon pathway is associated with effects on liver fat, which is why survodutide is being studied in MASLD alongside obesity. That dual interest distinguishes it from compounds developed for weight alone.
Its 49-week reporting period is shorter than the 68 to 72 weeks used by several other trials, which matters when comparing headline figures across studies.
Clinical evidence
What the trials showed
Mean weight reduction of 14.9% over 49 weeks
The first Phase 3 results published for a dual GLP-1/glucagon agonist. A separate programme is studying survodutide in obesity with metabolic dysfunction-associated steatotic liver disease.
What is known about tolerability
- Gastrointestinal effects were the most commonly reported events, consistent with the incretin class.
- As with other glucagon-receptor compounds, effects on heart rate and glucose handling are among those characterised during late-stage trials.
- The full profile is established through regulatory review, which has not concluded.
Availability
Not approved. Phase 3 data has been reported for obesity and further trials are ongoing in MASLD. Survodutide cannot be obtained lawfully for human use in the UK.
Survodutide: Common questions
What is survodutide?
Survodutide is an investigational once-weekly injection that activates both GLP-1 and glucagon receptors, developed by Boehringer Ingelheim. It produced 14.9% mean weight reduction over 49 weeks in Phase 3 and is also being studied in fatty liver disease. It is not approved by any regulator.
Why is survodutide being studied for liver disease?
Glucagon receptor agonism affects how the liver handles fat, so compounds acting on that pathway are of interest in metabolic dysfunction-associated steatotic liver disease as well as obesity. Survodutide has separate trial programmes in both.
Sources
Awaiting sign-off by a named clinician.